Trial ID # | NCT04140526 |
Phase | Ia/Ib |
Drug Class | Immunotherapy: Checkpoint Inhibitors/CTLA-4 |
Drug Name | Gotistobart |
Alternate Drug Names | ONC-392, BNT316 |
Drugs in Trial | Gotistobart |
Eligible Participant | Platinum resistant or refractory ovarian cancer |
Patients Enrolled | 32 |
Therapy Setting | Recurrence |
Study Design | Open-Label, Non-randomized |
Endpoints | ORR, DCR, evaluated per RECIST |
Efficacy | ORR: 21% (1CR, 5PR, n=28) |
Clinically Significant Adverse Events | Serious AE: 1 hypotensive chock |
Conclusion | ONC-392 as monotherapy shows encouraging anti-tumor activity in ovarian cancer |
Reference | Hays J et al. SAFETY AND CLINICAL ACTIVITIES OF THE ACID PHSENSITIVE ANTI-CTLA-4 MAB ONC-392 IN OVARIAN CANCER PATIENTS. SITC (2022) abstract 594 Hays J et al. Poster |